Business
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
Enrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors Update on JANX007 data and doses selected for
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":"\n\nEnrollment ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors\n\n\n\nUpdate on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024\n\n\n\nAppointed Eric Dobmeier and Natasha Hernday to the Board of Directors\n\n\n\nReceived $7.5 million development milestone payment from Merck\n\n\n\n$646.3 million in cash and cash equivalents and short-term investments at end of second quarter 2024\n\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the second quarter ended June 30, 2024, and provided a business update.\n\n\n“We are pleased with the progress we have made this quarter, particularly with the ongoing enrollment of our PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008) clinical trials. These advancements, along with the $7.5 million milestone payment from Merck, underscore the potential of our TRACTr and TRACIr platforms to develop transformative cancer therapies,” said David Campbell, Ph.D., President and CEO of Janux Therapeutics. “We are also excited to welcome Eric Dobmeier and Natasha Hernday to our Board of Directors. Their extensive experience and proven leadership in the biopharmaceutical industry will be invaluable as we continue to advance our pipeline and strategic goals.”\n\n\nRECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:\n\n\n\nThe company continues to enroll patients in the first-in-human Phase 1 clinical trial of JANX007 in mCRPC (NCT05519449) and JANX008 in advanced or metastatic solid tumors (NCT05783622). Janux anticipates providing an update on JANX007 data and doses selected for expansion cohorts in the second half of 2024. An update on JANX008 data is expected in 2025.\n\n\n\nBoard strengthened with key appointments.\n\n\nEric Dobmeier, J.D., has more than 20 years of experience in the biotechnology industry as both an executive and board member. Most recently, he was the President and CEO of Chinook Therapeutics, where he led the company through multiple strategic growth initiatives ultimately leading to its acquisition by Novarti...